Our commitment to advancing breast cancer research has led us on a remarkable journey of discovery and innovation.
1200.89
Status:
Closed
Title:
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Trial ID
A6181064, A6181107, A6181114
Status:
Closed
Title:
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Trial ID
AMEERA-5
Status:
Closed
Title:
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)
Trial ID
AMG 386
Status:
Closed
Title:
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Trial ID
AMG 706
Status:
Closed
Title:
An Open-label, Dose-finding Study to Evaluate the Safety of AMG 706 in Combination With Paclitaxel or Docetaxel as Treatment for Locally Recurrent or Metastatic Breast Cancer
Trial ID
ASLAN001-003
Status:
Closed
Title:
Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy
Trial ID
ATTAIN
Status:
Closed
Title:
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician’s Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)
Trial ID
B1891003
Status:
Closed
Title:
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Trial ID
Bali-1
Status:
Closed
Title:
Cetuximab and Cisplatin in the Treatment of “Triple Negative” (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer (BALI-1)
Trial ID
BAY 43-9006
Status:
Closed
Title:
A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Trial ID
BCIRG006
Status:
Closed
Title:
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Trial ID
BEATRICE
Status:
Closed
Title:
A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
Trial ID
Belle-2
Status:
Closed
Title:
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)
Trial ID
Belle-4
Status:
Closed
Title:
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4)
Trial ID
BETH
Status:
Closed
Title:
Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)
Trial ID
Big 1-98
Status:
Closed
Title:
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (BIG 1-98)
Trial ID
BO17708
Status:
Closed
Title:
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Trial ID
BO20231
Status:
Closed
Title:
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Trial ID
CBYL719A2201
Status:
Closed
Title:
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Trial ID
CHARIOT
Status:
Closed
Title:
Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment.
Trial ID
CheckMate 7A8
Status:
Closed
Title:
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (CheckMate 7A8)
Trial ID
CLAG525B2101
Status:
Closed
Title:
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Trial ID
CLCL161A2201
Status:
Closed
Title:
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Trial ID
CMCS110Z2201
Status:
Closed
Title:
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Trial ID
CONTESSA
Status:
Closed
Title:
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)
Trial ID
D8480C00007
Status:
Closed
Title:
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Trial ID
D-CARE
Status:
Closed
Title:
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Trial ID
ExteNET
Status:
Closed
Title:
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)
Trial ID
FACE
Status:
Closed
Title:
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (FACE)
Trial ID
Her2Climb
Status:
Closed
Title:
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)
Trial ID
JPBO
Status:
Closed
Title:
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Trial ID
KEYNOTE-119
Status:
Closed
Title:
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Trial ID
LUX-Breast 1
Status:
Closed
Title:
BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Trial ID
M12-895
Status:
Closed
Title:
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Trial ID
M12-914
Status:
Closed
Title:
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Trial ID
monarcHER
Status:
Closed
Title:
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)
Trial ID
NEOSPHERE
Status:
Closed
Title:
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Trial ID
PM0259 CA215BO
Status:
Closed
Title:
Phase II trial of oral Vinorelbine in combination with Capecitabine, and Trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
PMC_TTAC-0001-05
Status:
Closed
Title:
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
Trial ID
Puma_NER_6201
Status:
Closed
Title:
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Trial ID
SBT6050
Status:
Closed
Title:
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Trial ID
SHERsig
Status:
Closed
Title:
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
Trial ID
SOFT
Status:
Closed
Title:
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)
Trial ID
SPI-GCF-12-201
Status:
Closed
Title:
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Trial ID
TCD11418
Status:
Closed
Title:
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Trial ID
TEACH
Status:
Closed
Title:
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Trial ID
TH3RESA
Status:
Closed
Title:
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician’s Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)
Trial ID
TVEC_AMGEN
Status:
Closed
Title:
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Trial ID
TyN
Status:
Closed
Title:
Lapatinib and vinorelbine in women with previously treated breast cancer
Trial ID
VEG108838
Status:
Closed
Title:
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
Trial ID
More Information
For more information on clinical trials, get in contact with our Breast Clinical Trial Unit:
Breast Clinical Trials Unit (BCTU)
Business hours, Mon to Friday between 9am – 5pm
Email: BCTU@bcrc-wa.com.au
Phone: (08) 6500 5575